Showing 5241-5250 of 6661 results for "".
- Positive Dupixent Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe ADhttps://practicaldermatology.com/news/positive-dupixent-phase-3-data-in-children-aged-6-months-to-5-years-with-moderate-to-severe-ad/2461349/Dupixent significantly improved skin clearance, and reduced itch and overall disease severity in children as young as 6 months old, according to a new Phase 3 trial in the Lancet. Thes
- Chicken or the Egg? Unravelling the Role of Demodex in Rosaceahttps://practicaldermatology.com/news/chicken-or-the-egg-unravelling-the-role-of-demodex-in-rosacea/2461346/Researchers have long observed that microscopic mites that live as scavengers on normal human skin tend to occur in greater numbers on the faces of rosacea patients. It was unknown, however, whether the higher density of these Demodex, was a cause or an effect of this widespread disease.
- Meet the Cast of Allergan Aesthetics and BOTOX Cosmetic's New 'See Yourself' Campaignhttps://practicaldermatology.com/news/meet-the-cast-of-allergan-aesthetics-and-botox-cosmetics-new-see-yourself-campaign/2461344/Allergan Aesthetics is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX Cosmetic 'See Yourself' campaign. A After receiving nearly 20,000 submis
- Baby Dove Doubles Down Efforts to Close the Maternal Care Gap with #DearDoula and Greater Investment in Black Birth Equity Fundhttps://practicaldermatology.com/news/baby-dove-doubles-down-efforts-to-close-the-maternal-care-gap-with-deardoula-and-greater-investment-in-black-birth-equity-fund/2461342/Baby Dove is expanding the Black Birth Equity Fund, launching a new informative series called #DearDoula, and reinforcing existing strategic partnerships to help close the significant gap in care and health outcomes for Black mothers and their babies. "As a brand that encourages al
- Dermatologists Must Help Fight Climate Changehttps://practicaldermatology.com/news/dermatologists-must-help-fight-climate-change/2461339/Dermatologists should engage more meaningfully on key climate issues and to move beyond discussions of the skin-related impacts of climate change, according to a commentary in the International Journal of Dermatology.</
- EADV News: ‘Healthy’ Suntan Myths Persist in Europehttps://practicaldermatology.com/news/eadv-news-healthy-suntan-myths-persist-in-europe/2461338/Fully eight in 10 Europeans believe tans are attractive with almost as many (73%) saying tans are healthy, according to a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. Results from a survey, conducted by La Roche-Posay Laboratoires and
- Artemis Health, Zerigo Health Partner to Help Employers and Health Plans Better Evaluate and Manage Chronic Autoimmune Skin Conditionshttps://practicaldermatology.com/news/artemis-health-zerigo-health-partner-to-help-employers-and-health-plans-better-evaluate-and-manage-chronic-autoimmune-skin-conditions/2461335/Artemis Health and Zerigo Health are joining forces to helps employers, advisors, and health plans evaluate and manage benefits for their members with chronic autoimmune skin conditions such as psoriasis and atopic dermatitis. “Benefits leaders are inundated by hundreds of point s
- Cutera: Aviclear Hits 1,000 Treatment Markhttps://practicaldermatology.com/news/cutera-aviclear-hits-1000-treatment-mark/2461333/More than 1,000 AviClear laser acne treatments have been performed in the United States, Cutera reports. AviClear is FDA-cleared for the treatment of mild, moderate and severe acne. Additionally, AviClear recently received approval from Health Canada for the treatment of all severities
- Daxxify from Revance Gets FDA Greenlighthttps://practicaldermatology.com/news/daxxify-from-revance-gets-fda-greenlight/2461331/Daxxify™ (DaxibotulinumtoxinA-lanm) from Revance is FDA approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults. Daxxify is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum
- Allergan Aesthetics Hits Milestone: 100 Million Syringes of JUVÉDERM Shippedhttps://practicaldermatology.com/news/allergan-aesthetics-hits-milestone-100-million-syringes-of-juvederm-shipped/2461330/Drumroll, please…Allergan Aesthetics, an AbbVie company has produced and shipped 100 million syringes of JUVÉDERM products globally. Since its launch in 2000, the JUVÉDERM Collection of Fillers has grown to where its products are now avail